AssetMark’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$902 Buy
36
+5
+16% +$127 ﹤0.01% 3256
2026
Q2
$786 Hold
31
– – ﹤0.01% 3193
2026
Q1
$701 Hold
31
– – ﹤0.01% 3113
2025
Q4
$802 Hold
31
– – ﹤0.01% 2996
2025
Q3
$799 Buy
+31
New +$761 ﹤0.01% 2833
2018
Q1
– Sell
-3
Closed – – 1831
2017
Q4
$0 Buy
+3
New +$119 ﹤0.01% 2060

Other funds holding PCRX

AssetMark's PCRX Position: Q3 2026 in Review

AssetMark increased its Pacira BioSciences (PCRX) stake by 16% in Q3 2026, buying an estimated $127 and bringing the position to 36 shares worth $902. The position accounts for ﹤0.01% of the portfolio, ranked #3256.

AssetMark first reported a position in PCRX in Q4 2017 and has held it in 6 quarters since. 205 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • AssetMark held 36 shares of Pacira BioSciences worth $902 as of Q3 2026.
  • AssetMark bought 5 Pacira BioSciences shares in Q3 2026, an estimated $127.
  • Pacira BioSciences made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3256 holding.
  • AssetMark first reported a position in Pacira BioSciences in Q4 2017 and has held it in 6 quarters since.
  • 205 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.